Skip to NavigationSkip to content

PD-1 inhibitors

Sanofi and Regeneron in immuno-oncology push

Regeneron building
Regeneron is expanding its partnership with Sanofi

Pharma giants Sanofi and Regeneron are extending the partnership that brought new heart drug Praluent to the market, with a $2 billion deal to develop new antibodies to treat cancer.

This week the companies’ high cholesterol drug, Praluent (alirocumab) earned approval by the FDA and a positive recommendation from the EMA. The drug is a human monoclonal antibody targeting a protein called PCSK9 (proprotein convertase subtilisin/kexin type 9).

BMS sues Merck over new melanoma drug

merck image

Things are getting ugly between Bristol-Myers Squibb and Merck as the former company began legal proceedings against the latter over its new drug, which gained approval just last week.

In fact BMS filed the lawsuit against Merck’s new melanoma treatment Keytruda (pembrolizumab) on the same day it was approved by the FDA.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches